Sanara MedTech Inc. Reports First Quarter 2026 Financial Results
Sanara MedTech Inc. reported a net revenue growth of 19% for the first quarter of 2026, reaching $27.8 million compared to $23.4 million in the same period of 2025. The company achieved GAAP net profitability of $0.04 per fully diluted share, with significant contributions from soft tissue repair product sales despite a slight decline in bone fusion products. Sanara’s gross margin improved to 93%, reflecting better sales and operational strategies. The company continues to strengthen its sales team and expand its market reach.
Net Revenue Growth of 19% and Net Profitability from Continuing Operations of $0.04 Per Fully Diluted Share for the Quarter